Boxer Capital’s Aligos Therapeutics ALGS Stock Holding History

Boxer Capital’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-61,042	Closed	-$1.85M	–	74
2022 Q2	$1.85M	Hold	61,042	–	–	0.12%	69
2022 Q1	$3.28M	Hold	61,042	–	–	0.17%	64
2021 Q4	$18.1M	Hold	61,042	–	–	0.7%	33
2021 Q3	$23.7M	Hold	61,042	–	–	0.83%	35
2021 Q2	$31.1M	Hold	61,042	–	–	1.1%	25
2021 Q1	$34.7M	Hold	61,042	–	–	1.18%	27
2020 Q4	$42.2M	Buy	+61,042	New	+$29.7M	1.36%	22

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital's ALGS Position: Q3 2022 in Review

Boxer Capital sold out of Aligos Therapeutics (ALGS) in Q3 2022, closing a stake of 61,042 shares — an estimated $1.85M sold.

Boxer Capital first reported a position in ALGS in Q4 2020 and held it in 7 quarters. The position peaked at $42.2M in Q4 2020. 52 funds tracked by Wall St. Rank hold ALGS as of Q3 2022.

Boxer Capital reported no remaining Aligos Therapeutics position as of Q3 2022 after selling out during the quarter.
Boxer Capital sold 61,042 Aligos Therapeutics shares in Q3 2022, an estimated $1.85M.
Boxer Capital first reported a position in Aligos Therapeutics in Q4 2020 and held it in 7 quarters.
Boxer Capital's Aligos Therapeutics position peaked at $42.2M in Q4 2020.
52 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2022.

Based on Boxer Capital's 13F filing for Q3 2022, filed 14 Nov 2022.